CA
ZNTL icon

Carson Advisory’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Carson Advisory’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.5K Sell
23,270
-200
-0.9% -$517 0.03% 188
2025
Q4 		$31.7K Sell
23,470
-8,600
-27% -$12.5K 0.02% 183
2025
Q3 		$48.4K Buy
32,070
+2,500
+8% +$3.75K 0.03% 173
2025
Q2 		$34.3K Hold
29,570
– – 0.02% 171
2025
Q1 		$47K Buy
29,570
+4,900
+20% +$10.6K 0.03% 164
2024
Q4 		$74.8K Buy
24,670
+100
+0.4% +$328 0.05% 157
2024
Q3 		$90.4K Buy
24,570
+8,800
+56% +$32K 0.06% 177
2024
Q2 		$64.5K Buy
15,770
+3,000
+23% +$33.5K 0.05% 166
2024
Q1 		$201K Buy
+12,770
New +$176K 0.14% 164

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Carson Advisory's ZNTL Position: Q1 2026 in Review

Carson Advisory reduced its Zentalis Pharmaceuticals (ZNTL) stake by 0.85% in Q1 2026, selling an estimated $517 and leaving 23,270 shares worth $54.5K. The position accounts for 0.03% of the portfolio, ranked #188.

Carson Advisory first reported a position in ZNTL in Q1 2024 and has held it in 9 quarters since. The position peaked at $201K in Q1 2024. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Carson Advisory held 23,270 shares of Zentalis Pharmaceuticals worth $54.5K as of Q1 2026.
  • Carson Advisory sold 200 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $517.
  • Zentalis Pharmaceuticals made up 0.03% of Carson Advisory's portfolio in Q1 2026, its #188 holding.
  • Carson Advisory first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Carson Advisory's Zentalis Pharmaceuticals position peaked at $201K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Carson Advisory's 13F filing for Q1 2026, filed 7 May 2026.